Abstract
Indole-3-carbinol (I3C) is a naturally occurring anticancer agent and has entered clinical trials for cancer prevention. However, the clinical development of I3C has been impeded by its poor metabolic profile. The active components of I3C were used to develop a novel class of indole analogs to optimize I3C's anticancer actions, including blocking growth factor-stimulated Akt activation. The most promising of these analogs, SRI3668, exhibited potent oral anticancer activity against various cancers and no significant toxicity.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 3412-3415 |
| Number of pages | 4 |
| Journal | Journal of medicinal chemistry |
| Volume | 50 |
| Issue number | 15 |
| DOIs | |
| State | Published - Jul 26 2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Computer-aided rational drug design: A novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS